Indications |
Oral Psychoses Adult: Initially, 20-60 mg wkly, increased up to 250 mg once a wk in severe or resistant conditions. |
Contraindications |
Preexisting CNS depression or coma. |
Warnings / Precautions |
Pregnancy and lactation; elderly; epilepsy; preexisting cardiac conduction problems; hypokalaemia, hypomagnesemia; hypothyroidism. |
Adverse Reactions |
Lower threshold for seizures, blurring of vision, dry mouth, retention of urine, constipation, orthostatic hypotension, weight gain, impaired glucose tolerance, allergic skin rashes, cholestatic jaundice; extrapyramidal effects; delirium; agitation, anxiety, depression, euphoria; anorexia, constipation, diarrhoea; alopecia; amenorrhoea, hypoglycaemia; hyponatraemia; hypersalivation, nausea, vomiting; bronchospasm; reported increased risk of breast cancer. Potentially Fatal: Blood dyscrasias; neuroleptic malignant syndrome; alteration of heart conduction leading to QT prolongation and life threatening arrhythmias. |
Overdose Reactions |
Symptoms: deep sleep, dystonia, extrapyramidal symptoms. Treatment: supportive and symptom specific. |
Drug Interactions |
Orthostatic hypotension with MAOIs; may increase sedation with alcohol, hypnotics, antihistamines, opiates; antacids containing aluminum salts may decrease absorption; additive antimuscarinic effects with TCAs; may reduce bromocriptine's ability to reduce serum prolactin; amphetamines may increase psychosis; may inihibit antiparkinsonian effects of levodopa; may increase risk of extrapyrimidal symptoms with metoclopramide; may increase phenytoin levels (phenytoin may reduce penfluridol levels); possible additive effects on QT interval with type 1a antiarrhythmics, TCAs, some quinolone antibiotics (e.g. moxifloxacin), may have additive hypotensive effects with trazodone; may increase levels of valproic acid. Potentially Fatal: May produce neurotoxicity with lithium. See Below for More penfluridol Drug Interactions |
Food Interactions |
Avoid valerian, St John's wort, kava kava, gotu kola; increased risk of CNS depression. |
Mechanism of Actions |
Penfluridol blocks the postsynaptic dopamine receptor in the mesolimbic dopaminergic system and inhibits the release of hypothalamic and hypophyseal hormones. Duration: 1 wk. Absorption: Absorbed from the GI tract (oral); peak plasma concentrations after 2 hr. Metabolism: Undergoes enterohepatic recycling. Excretion: Urine and faeces (as N-dealkylated metabolite). Elimination half-life: 36 hr (initial), 120 hr (terminal). |
ATC Classification |
N05AG03 - penfluridol ; Belongs to the class of diphenylbutylpiperidine derivatives antipsychotics. |
Available As |
|
Penfluridol
Post Review about Penfluridol Click here to cancel reply.
Penfluridol Containing Brands
Penfluridol is used in following diseases
Drug - Drug Interactions of Penfluridol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.